Lercanidipino en pacientes diabéticos con insuficiencia renal

摘要: OBJECTIVE To evaluate the safe use of a new calcium channel blocker, lercanidipine, in diabetic chronic renal failure (CRF) patients. DESIGN AND METHODS The study recruited 42 CRF patients (creatinine > 1.4 mg/dl for males, creatinine 1.2 females, or clearance < 70 ml/min). Mean age was 68.2 +/- 9.1 years. 53.8% were males and 46.2% females. Three type 1 diabetics 39 ones II. All receiving ACE inhibitors (67.4%) angiotensin II antagonist (32.6%) therapy but they had higher blood pressure than recommended (130/85 mmHg). No under diuretic treatment. Patients clinically evaluated 1, 3 6 months after starting treatment with lercanidipine. Samples urine examination taken during examination. When needed, third drug added to treatment, excluding diuretics. Creatinine measured using 24 h collection. RESULTS BP significantly decrease from 163 18/90 8 mmHg 134 12/77 9 mmHg. One half showed significant reduction pressure, 26.7% reached target (< 130/85 mmHg) 20.0% gets optimal control one patient untoward effects. edema detected nor adverse effects related vasodilatation found. Plasmatic did not change (1.9 0.5 baseline vs 1.8 mg/dl) increased at end visit (40.1 14.5 45.4 18.2 ml/min) difference significant. Proteinuria unchanged. CONCLUSIONS Lercanidipine good antihypertensive effect It has tolerability profile neutral on plasmatic lipids. Neither impairment function increment proteinuria detected.